Novo Nordisk raises 2026 outlook following strong Wegovy pill sales
Novo Nordisk raised its full-year adjusted sales and operating profit outlook to -2% to +2% growth, driven by GLP-1 volume growth in obesity treatments.
Checked against 3 sourcesCNBCuk.finance.yahoo.comstocktitan.net
